{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:33:57Z","timestamp":1762432437559,"version":"3.37.3"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["SARCI170803258878","IFR200909250002"],"award-info":[{"award-number":["SARCI170803258878","IFR200909250002"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.trim.2024.102045","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T02:26:17Z","timestamp":1713407177000},"page":"102045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Early recovery of natural killer cells post T-cell depleted allogeneic stem cell transplantation using alemtuzumab \u201cin the bag\u201d"],"prefix":"10.1016","volume":"84","author":[{"given":"Glenda M.","family":"Davison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica J.","family":"Opie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saarah F.G.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rygana","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Novitzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9674","key":"10.1016\/j.trim.2024.102045_bb0005","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.trim.2024.102045_bb0010","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1385\/MO:19:2S:S33","article-title":"Alemtuzumab in stem cell transplantation","volume":"19","author":"Hale","year":"2002","journal-title":"Med. Oncol."},{"issue":"8","key":"10.1016\/j.trim.2024.102045_bb0015","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/14712598.2011.592824","article-title":"Alemtuzumab in allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Poir\u00e9","year":"2011","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.trim.2024.102045_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2019.06.001","article-title":"Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft","volume":"57","author":"Loeff","year":"2019","journal-title":"Transpl. Immunol."},{"issue":"2","key":"10.1016\/j.trim.2024.102045_bb0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/14653240310004520","article-title":"Campath-1 abs \u2018in the bag\u2019 for hematological malignancies: the Cape Town experience","volume":"6","author":"Novitzky","year":"2004","journal-title":"Cytotherapy"},{"key":"10.1016\/j.trim.2024.102045_bb0030","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.bmt.1703248","article-title":"Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation","volume":"28","author":"Chakraverty","year":"2001","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.trim.2024.102045_bb0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood-2006-07-038687","article-title":"Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value","volume":"110","author":"Ruggeri","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.trim.2024.102045_bb0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jcyt.2020.08.003","article-title":"Effect of alemtuzumab-based T-cell depletion on graft compositional change in vitro and immune reconstitution early after allogeneic stem cell transplantation","volume":"23","author":"Roex","year":"2021","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.trim.2024.102045_bb0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/imr.12157","article-title":"The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT)","volume":"258","author":"Foley","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.trim.2024.102045_bb0050","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.bbmt.2016.09.006","article-title":"Early natural killer cell reconstitution predicts overall survival in T-cell replete allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Minculescu","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2024.102045_bb0055","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fimmu.2016.00144","article-title":"Functional reconstitution of natural killer cells in allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ullah","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trim.2024.102045_bb0060","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.3389\/fimmu.2019.02794","article-title":"Mavilio D innate immune responses in the outcome of haploidentical hematopoietic stem cell transplantation to cure haematological malignancies","volume":"10","author":"Zaghi","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.trim.2024.102045_bb0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with post-transplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.trim.2024.102045_bb0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/scd.1.1996.5.213","article-title":"The ISHAGE guidelines for CD34+ cell determination by flow cytometry","volume":"5","author":"Dr","year":"1996","journal-title":"J. Hematother."},{"issue":"6","key":"10.1016\/j.trim.2024.102045_bb0075","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/bmt.2016.18","article-title":"Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the worldwide network for blood and marrow transplantation group including the global survey","volume":"51","author":"Niederwieser","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.trim.2024.102045_bb0080","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post transplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2024.102045_bb0085","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood-2003-04-1200","article-title":"Reconstitution of dendritic and natural killer cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand","volume":"103","author":"Chklovskaia","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.trim.2024.102045_bb0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbmt.2007.12.497","article-title":"Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies","volume":"14","author":"Chang","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.trim.2024.102045_bb0095","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/leu.2009.269","article-title":"CD3+\/CD19+-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation leads to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A","volume":"24","author":"Eissens","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.trim.2024.102045_bb0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/146532401317070899","article-title":"Pharmacokinetics of CAMPATH-1H in BMT patients","volume":"3","author":"Rebello","year":"2001","journal-title":"Cytotherapy"},{"key":"10.1016\/j.trim.2024.102045_bb0105","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.bbmt.2013.10.001","article-title":"Definition of the variables affecting efficacy of immunodepletion ex vivo of peripheral blood progenitor cell grafts by alemtuzumab (Campath in the bag)","author":"Novitzky","year":"2013","journal-title":"Biol. Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.trim.2024.102045_bb0110","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.4049\/jimmunol.1502570","article-title":"Human CD56bright NK cells: an update","volume":"196","author":"Michel","year":"2016","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.trim.2024.102045_bb0115","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bbmt.2009.10.021","article-title":"The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings","volume":"16","author":"Clausen","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2024.102045_bb0120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12185-017-2379-x","article-title":"NK cell therapy after hematopoietic stem cell transplantation: can we improve anti tumor effect?","volume":"107","author":"Van Elssen","year":"2018","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.trim.2024.102045_bb0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41375-021-01349-4","article-title":"Decrease in post-transplant relapse using donor-derived expanded NK-cells","volume":"36","author":"Ciurea","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.trim.2024.102045_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039416","article-title":"Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis","volume":"7","author":"Rao","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.trim.2024.102045_bb0135","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/sj.leu.2404892","article-title":"Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia","volume":"21","author":"Savani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.trim.2024.102045_bb0140","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/ajh.25983","article-title":"NK cell alloreactivity in acute myeloid leukemia in the post-transplant cyclophosphamide era","volume":"95","author":"Van Elssen","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.trim.2024.102045_bb0145","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fimmu.2020.02022","article-title":"Influence of KIR, and NK cell reconstitution in the outcomes of hematopoietic stem cell transplantation","volume":"11","author":"Gao","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.trim.2024.102045_bb0150","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.coi.2012.01.001","article-title":"NK cell MHC class I specific receptors (KIR): from biology to clinical intervention","volume":"24","author":"Thielens","year":"2012","journal-title":"Curr. Opin. Immunol."},{"issue":"4","key":"10.1016\/j.trim.2024.102045_bb0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.it.2005.02.007","article-title":"Cellular ligands of activating NK receptors","volume":"26","author":"Bottino","year":"2005","journal-title":"Trends Immunol."},{"issue":"11","key":"10.1016\/j.trim.2024.102045_bb0160","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1172\/JCI90387","article-title":"CD56bright NK cells exhibit potent antitumor responses following IL-15 priming","volume":"127","author":"Wagner","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trim.2024.102045_bb0165","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/eji.201747134","article-title":"NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD","volume":"48","author":"Chan","year":"2018","journal-title":"Eur. J. Immunol."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327424000613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327424000613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T02:55:23Z","timestamp":1716951323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327424000613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":33,"alternative-id":["S0966327424000613"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2024.102045","relation":{},"ISSN":["0966-3274"],"issn-type":[{"type":"print","value":"0966-3274"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early recovery of natural killer cells post T-cell depleted allogeneic stem cell transplantation using alemtuzumab \u201cin the bag\u201d","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2024.102045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102045"}}